Ethical Considerations for Unblinding a Participant's Assignment to Interpret a Resolved Adverse Event

Affiliations

¹ a Treuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital and Research Institute, and University of Washington School of Medicine.
² b Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Berman Institute of Bioethics.
³ c St. Jude Children's Research Hospital.

Case Reports

Benjamin S Wilfond et al. Am J Bioeth. 2018 Oct.

. 2018 Oct;18(10):66-67.

doi: 10.1080/15265161.2018.1522167.

¹ a Treuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital and Research Institute, and University of Washington School of Medicine.
² b Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Berman Institute of Bioethics.
³ c St. Jude Children's Research Hospital.

No abstract available

Comment in

The Scientific and Social Implications of Unblinding a Study Subject.
Quittell LM. Quittell LM. Am J Bioeth. 2018 Oct;18(10):71-73. doi: 10.1080/15265161.2018.1513589. Am J Bioeth. 2018. PMID: 30339067 No abstract available.
Considerations for Unblinding in Biopharmaceutical Industry Sponsored Trials.
Shah JJ, Bond J. Shah JJ, et al. Am J Bioeth. 2018 Oct;18(10):68-70. doi: 10.1080/15265161.2018.1513588. Am J Bioeth. 2018. PMID: 30339068 No abstract available.
Blinds and Research Risks.
Steel R, Danis M. Steel R, et al. Am J Bioeth. 2018 Oct;18(10):70-71. doi: 10.1080/15265161.2018.1513590. Am J Bioeth. 2018. PMID: 30339079 No abstract available.